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Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the 5th most common
cause of years of life lost globally by 2040. CKD is a major cause of catastrophic health expenditure. The costs of dialysis and
transplantation consume up to 3% of the annual healthcare budget in high-income countries. However, the onset and
progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive
interventions – be it primary, secondary, or tertiary. This article focuses on outlining and analyzing measures that can be
implemented in every country to promote and advance CKD prevention. Primary prevention of kidney disease should focus on
the modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, as well as exposure to
environmental risk factors and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood
pressure optimization and glycemic control, should be the main goal of education and clinical interventions. In patients with
advanced CKD, management of co-morbidities such as uremia and cardiovascular disease is a highly recommended
preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are needed to proliferate the
preventive approach. While national policies and strategies for non-communicable diseases might be present in a country,
specific policies directed toward education and awareness about CKD screening, management, and treatment are often
lacking. Hence, there is an urgent need to increase the awareness of preventive measures throughout populations,
professionals, and policy makers.
Key words: Kidney diseases; Prevention; Detection; Awareness
Correspondence: P. Kam-Tao Li: <philipli@cuhk.edu.hk4 | K. Kalantar-Zadeh: okkz@uci.edu>
*This article was originally published in Kidney International (doi: https://doi.org/10.1016/j.kint.2019.12.002) and is reprinted concurrently
in several journals. The articles cover identical concepts and wording, but vary in minor stylistic and spelling changes, detail, and length
of manuscript in keeping with each journal’s style. Any of these versions may be used in citing this article. The permission of
republication herein was granted by the authors, the journal, and its publisher.
Received November 19, 2019 | Accepted January 8, 2020
Braz J Med Biol Res | doi: 10.1590/1414-431X20209614
Brazilian Journal of Medical and Biological Research (2020) 53(3): e9614, http://dx.doi.org/10.1590/1414-431X20209614
ISSN 1414-431X Editorial
1/10
Introduction
Around 850 million people currently are affected by
different types of kidney disorders (1). Up to one in ten
adults worldwide has chronic kidney disease (CKD), which
is invariably irreversible and mostly progressive. The global
burden of CKD is increasing, and CKD is projected to
become the 5th most common cause of years of life lost
globally by 2040 (2). If CKD remains uncontrolled and if the
affected person survives the ravages of cardiovascular and
other complications of the disease, CKD progresses to
end-stage renal disease (ESRD), where life cannot be
sustained without dialysis therapy or kidney transplanta-
tion. Hence, CKD is a major cause of catastrophic health
expenditure (3). The costs of dialysis and transplantation
consume 2–3% of the annual health-care budget in high-
income countries, spent on less than 0.03% of the total
population of these countries (4).
Importantly, however, kidney disease can be prevented
and progression to ESRD can be delayed with appropriate
access to basic diagnostics and early treatment including
life style modifications and nutritional interventions (4–8).
Despite this, access to effective and sustainable kidney
care remains highly inequitable across the world, and kidney
disease remains a low health priority in many countries.
Kidney disease is missing from the international agenda
for global health. Notably absent from the impact indica-
tors for the Sustainable Development Goal 3, Target 3.4
(by 2030, reduce by one third premature mortality from
non-communicable diseases (NCDs) through prevention
and treatment and promote mental health and well-being)
and the latest iteration of the Untied Nation (UN) Political
Declaration on NCDs, kidney diseases urgently need to
be given political attention, priority, and consideration (9).
Current global political commitments on NCDs focus largely
on four main diseases: cardiovascular disease (CVD),
cancer, diabetes, and chronic respiratory diseases. Yet, it is
estimated that 55% of the global NCD burden is attributed
to diseases outside of this group (10). Furthermore, kidney
disease frequently co-exists with the ‘big’ four NCDs,
which leads to worse health outcomes. CKD is a major
risk factor for heart disease and cardiac death, as well as
for infections such as tuberculosis, and is a major compli-
cation of other preventable and treatable conditions includ-
ing diabetes, hypertension, HIV, and hepatitis (4–7). As
the Sustainable Development Goals and Universal Health
Coverage agendas progress and provide a platform for
raising awareness of NCD health care and monitoring
needs, targeted action on kidney disease prevention
should become integral to the global policy response (1).
The global kidney health community calls for the recogni-
tion of kidney disease and effective identification and
management of its risk factors as a key contributor to
the global NCD burden and the implementation of an inte-
grated and people’s centered approach to care.
Definition and classification of CKD
prevention
According to the expert definitions including the Center
for Disease Control and Prevention (11), the term ‘‘pre-
vention’’ refers to activities that are typically categorized
by the following three definitions: 1) Primary Prevention
implies intervening before health effects occur in an effort
to prevent the onset of illness or injury before the disease
process begins; 2) Secondary Prevention suggests pre-
ventive measures that lead to early diagnosis and prompt
treatment of a disease to prevent more severe problems
and includes screening to identify diseases in the earliest
stages; and 3) Tertiary Prevention indicates managing
disease after it is well established in order to control
disease progression and the emergence of more severe
complications, which is often by means of targeted
measures such as pharmacotherapy, rehabilitation, and
screening for and management of complications. These
definitions have important bearing on the prevention and
management of CKD, and accurate identification of risk
factors that cause CKD or lead to faster progression to
renal failure as shown in Figure 1 are relevant in health
policy decisions and health education and awareness
related to CKD (12).
Primary prevention of CKD
The incidence (new cases) and prevalence (cumulative
pre-existing cases) of CKD have been rising worldwide
(13). This primary level of prevention requires aware-
ness of modifiable CKD risk factors and efforts to focus
healthcare resources on those patients who are at the
highest risk of developing new onset or de novo CKD.
Measures to achieve effective primary prevention should
focus on the two leading risk factors for CKD including
diabetes mellitus and hypertension. Evidence suggests
that an initial mechanism of injury is renal hyperfiltration
with seemingly elevated glomerular filtration rate (GFR),
above normal ranges. This is often the result of glomerular
hypertension that is often seen in patients with obesity or
diabetes mellitus, but it can also occur after a high dietary
protein intake (8). Other CKD risk factors include poly-
cystic kidneys or other congenital or acquired structural
anomalies of the kidney and urinary tracts, primary glo-
merulonephritis, exposure to nephrotoxic substances or
medications (such as nonsteroidal anti-inflammatory drugs),
having one single kidney, e.g., solitary kidney after cancer
nephrectomy, high dietary salt intake, inadequate hydra-
tion with recurrent volume depletion, heat stress, exposure
to pesticides and heavy metals (as has been speculated
as the main cause of Mesoamerican nephropathy), and
possibly high protein intake in those at higher risk of CKD
(8). Among non-modifiable risk factors are advancing age
and genetic factors such as apolipoprotein 1 (APOL1) gene
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that is mostly encountered in those with sub-Saharan
African ethnicity, especially among African Americans.
Certain disease states may cause de novo CKD such as
cardiovascular and atheroembolic diseases (also known
as secondary cardiorenal syndrome) and liver diseases
(hepatorenal syndrome). Table 1 shows some of the risk
factors of CKD.
Among measures to prevent emergence of de novo
CKD are screening efforts to identify and manage persons
at high risk of CKD, especially those with diabetes mellitus
and hypertension. Hence, targeting primordial risk factors
of these two conditions including metabolic syndrome and
overnutrition is relevant to primary CKD prevention as is
correcting obesity (14). Promoting healthier lifestyle is an
important means to that end including physical activity and
healthier diet. The latter should be based on more plant-
based foods with less meat, less sodium intake, more
complex carbohydrates with higher fiber intake, and less
saturated fat. In those with hypertension and diabetes,
optimizing blood pressure and glycemic control has shown
to be effective in preventing diabetic and hypertensive ne-
phropathies. A recent expert panel suggested that persons
with solitary kidney should avoid high protein intake above
1 g/kg body weight per day (15). Obesity should be avoided,
and weight reduction strategies should be considered (14).
Secondary prevention in CKD
Evidence suggests that among those with CKD, the
vast majority have early-stage of the disease. i.e., CKD
stages 1 and 2 with microalbuminuria (30 to 300 mg/day)
or CKD stage 3B (eGFR between 45 to 60 mL min–1 
(1.73 m2)–1) (16). In these persons with preexisting
disease, the ‘‘secondary prevention’’ of CKD has the
highest priority. For these earlier stages of CKD, the main
goal of kidney health education and clinical interventions
is how to slow disease progression. Uncontrolled or poorly
controlled hypertension is one of the most established risk
factors for faster CKD progression. The underlying patho-
physiology of faster CKD progression relates to ongoing
damage to the kidney structure and loss of nephrons with
worsening interstitial fibrosis as occurs with sustained
hypertension.
The cornerstone of pharmacotherapy in secondary
prevention is the use of angiotensin pathway modulators,
also known as renin-angiotensin-aldosterone system
Figure 1. Overview of the preventive measures in chronic kidney disease (CKD) to highlight the similarities and distinctions
pertaining to primary, secondary, and tertiary preventive measures and their intended goals. AKI: acute kidney injury; GFR:
glomerular filtration rate; BP: blood pressure; RAASi: renin-angiotensin-aldosterone system inhibitors; SGLT2i: sodium-glucose
cotransporter-2 inhibitors.
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Table 1. Risk factors for de novo chronic kidney disease (CKD) and pre-existing CKD progression.
Risk Factor* Contribution to de novo CKD Contribution to CKD progression
Diabetes mellitus B50% of all CKDs
Hypertension B25% of all CKDs
Obesity 10–20%
Age Seen with advancing age, especially in
the setting of comorbid conditions
Some suggest that older CKD
patients may have slower
progression
Race, genetics, and other hereditary factors
APOL1 gene
Hereditary nephritis (Alport’s)
Common among those with African
American ancestors
Acute glomerulonephritis (GN)
Post-infectious GN
Rapidly progressive GN
o10% Recurrent GN or exacerbation of
proteinuria
Polycystic kidney disorders o10%, family history of cystic kidney
disorders
Acute kidney injury (AKI)
Acute tubular necrosis (ATN)
Acute interstitial nephritis (AIN)
Repeated AKI bouts can cause CKD Repeated AKI bouts can accelerate
CKD progression
Autoimmune disorders
Lupus erythematosus
Other connective tissue disorders
Pharmacologic
Medications causing interstitial nephritides
(NSAIDs, CNI, chemotherapy, PPI, etc) or ATN
(aminoglycosides)
Herbs and herbal medication
Variable, e.g., in Taiwan, Chinese herb
nephropathy may be an important
contributor
Environmental
Heavy metal exposure
Rare
Acquired or congenital solitary kidney
Cancer, donor or traumatic nephrectomy
Congenital solitary kidney, unilateral atrophic kidney
Acquired urinary tract disorders & obstructive
nephropathy
Benign prostate hyperplasia in men
Gynecological cancers in women
Congenital anomalies of the kidney and urinary tract Mostly in children and young adults
Inadequate fluid intake
Mesoamerican nephropathy
Others
Unknown risk, but high prevalence is
suspected in Central America
Whereas in earlier CKD stages
adequate hydration is important to
avoid pre-renal AKI bouts, higher
fluid intake in more advanced CKD
may increase the risk of
hyponatremia
High protein intake Unknown risk, recent data suggest
higher CKD risk or faster CKD
progression with high protein diet, in
particular from animal sources
Higher protein intake can accelerate
the rate of CKD progression
Cardiovascular diseases (cardiorenal) Ischemic nephropathy
Liver disease (hepatorenal) Non-alcoholic steatohepatitis, viral
hepatitis
*Many of these risk factors contribute to both de novo CKD and its faster progression and, hence, are relevant to both primary and
secondary prevention.
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inhibitors (RAASi). These drugs reduce both systemic
blood pressure and intraglomerular pressure by opening
efferent arterioles of the glomeruli, hence, leading to
longevity of the remaining nephrons. Low protein diet
appears to have a synergistic effect on RAASi therapy
(17). In terms of the potential effect of controlling glycemic
status and correcting obesity on the rate of CKD progres-
sion, there are mixed data. However, recent data suggest
that a new class of anti-diabetic medications known as
sodium-glucose cotransporter-2 inhibitors (SGLT2i) can
slow CKD progression, but this effect may not be related
to the glycemic modulation of the medication. Whereas
acute kidney injury (AKI) may or may not cause de novo
CKD, AKI events that are superimposed on preexisting
CKD may accelerate disease progression (18). A rela-
tively recent case of successful secondary prevention that
highlights the significance of implementing preventive
strategies in CKD is the use of a vasopressin type-2-receptor
antagonists in adult polycystic kidney disease (19).
Tertiary prevention in CKD
In patients with advanced CKD, management of
uremia and related comorbid conditions such as anemia,
mineral and bone disorders, and cardiovascular disease
is of high priority, so that these patients can achieve the
highest longevity. These measures can be collectively
referred to as ‘‘tertiary prevention’’ of CKD. In these indi-
viduals, cardiovascular disease burden is exceptionally
high, especially if they have underlying diabetes or hyper-
tension, while they often do not follow other traditional
profiles of cardiovascular risk such as obesity or hyperlip-
idemia. Indeed, in these patients, a so-called ‘‘reverse
epidemiology’’ exists, in that hyperlipidemia and obesity
appear to be protective at this advanced stage of CKD.
This could be due to the overshadowing impact of
the ‘‘protein-energy wasting’’ (PEW) that happens more
frequently with worsening uremia and which is associated
with weight loss and poor outcomes including cardiovas-
cular disease and death. Whereas many of these patients,
if they survive the ravages of PEW and cardiovascular
disease, will eventually receive renal replacement therapy
in the form of dialysis therapy or kidney transplantation,
a new trend is emerging to maintain them longer without
dialysis by implementing conservative management of
CKD. However, in some with additional comorbidities such
as metastatic cancers, palliative measures with supportive
care can be considered.
Approaches to identification of CKD
The lack of awareness of CKD around the world is one
of the reasons for late presentation of CKD in both
developed and developing economies (20–22). The overall
CKD awareness among the general population and even
high cardiovascular risk groups across 12 low-income and
middle-income countries (LMIC) was less than 10% (22).
Given its asymptomatic nature, screening of CKD
plays an important role in early detection. Consensus and
positional statements have been published by the Inter-
national Society of Nephrology (ISN) (23), the National
Kidney Foundation (24), the Kidney Disease Improving
Global Outcomes (25), the NICE Guidelines (26), and
the Asian Forum for CKD Initiatives (27). There was a
lack of trials to evaluate screening and monitoring of CKD
(28). Currently, most will promote a targeted screening
approach to early detection of CKD. Some of the major
groups at risk for targeted screening include: patients with
diabetes, hypertension, those with family history of CKD,
individuals receiving potentially nephrotoxic drugs, herbs
or substances or taking indigenous medicine, patients with
past history of acute kidney injury, and individuals older
than 65 years of age (27,29). CKD can be detected with
2 simple tests: a urine test for the detection of proteinuria
and a blood test to estimate the GFR (24,27).
Given that currently population screening for CKD
is not recommended and it was claimed that it might
add unintended harm to the general population being
screened (28), there is no specialty society or preventive
services group that recommends general screening (30).
LMIC are ill-equipped to deal with the devastating con-
sequences of CKD, particularly the late stages of the
disease. There are suggestions that screening should
primarily include high-risk individuals, but also extend to
those with suboptimal levels of risk, e.g., prediabetes and
prehypertension (31).
Cost-effectiveness of early detection
programs
Universal screening of the general population would
be time-consuming, expensive, and has been shown to
be not cost-effective. Unless selectively directed towards
high-risk groups, such as the case of CKD in disadvan-
taged populations (32), according to a cost-effectiveness
analysis using a Markov decision analytic model, popu-
lation-based dipstick screening for proteinuria has an
unfavorable cost effectiveness ratio (33). A more recent
Korean study confirmed that their National Health Screen-
ing Program for CKD is more cost-effective for patients
with diabetes or hypertension than the general population
(34). From an economic perspective, screening CKD by
detection of proteinuria was shown to be cost-effective
in patients with hypertension or diabetes in a systematic
review (35). The incidence of CKD, rate of progression,
and effectiveness of drug therapy were major drivers of
cost-effectiveness and thus CKD screening may be more
cost-effective in populations with higher incidences of
CKD, rapid rates of progression, and more effective drug
therapy.
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A rational approach to CKD early detection
The approach towards CKD early detection will include
the decision for frequency of screening, who should
perform the screening, and intervention after screening
(21). Screening frequency for targeted individuals should
be yearly if no abnormality is detected on initial evaluation.
This is in line with the Kidney Disease Improving Global
Outcomes (KDIGO) resolution that the frequency of test-
ing should be according to the target group to be tested
and generally needs not be more frequent than once per
year (25). Who should perform the screening is always
a question especially when the healthcare professional
availability is a challenge in lower income countries.
Physicians, nurses, paramedical staff, and other trained
healthcare professionals are eligible to do the screening
tests. Intervention after screening is also important and
patients detected with CKD should be referred to primary
care and general physicians with experience in manage-
ment of kidney disease for follow up. A management
protocol should be provided to the primary care and
general physicians. Further referral to nephrologists for
management should be based on well-defined protocols
(22,25,27).
Integration of CKD prevention into national
NCD programs
Given the close links between CKD and other NCDs, it
is critical that CKD advocacy efforts be aligned with existing
initiatives concerning diabetes, hypertension, and cardio-
vascular disease, particularly in LMIC. Some countries and
regions have successfully introduced CKD prevention
strategies as part of their NCD programs. As an example,
in 2003, a kidney health promotion program was introduced
in Taiwan, with its key components including a ban on
herbs containing aristolochic acid, public-awareness cam-
paigns, patient education, funding for CKD research, and
the setting up of teams to provide integrated care (36). In
Cuba, the Ministry of Public Health has implemented a
national program for the prevention of CKD. Since 1996 the
program has followed several steps: 1) the analysis of the
resources and health situation in the country; 2) epidemio-
logical research to define the burden of CKD; and 3);
continuing education for nephrologists, family doctors, and
other health professionals. The main goal has been to bring
nephrology care closer to the community through a regional
redistribution of nephrology services and joint management
of CKD patients by primary healthcare physicians and
nephrologists (37). The integration of CKD prevention into
NCDs program has resulted in the reduction of renal and
cardiovascular risks in the general population. Main out-
comes have been the reduction in the prevalence of risk
factors, such as low birth weight, smoking, and infectious
diseases. There has been an increased rate of the diagnosis
of diabetes and of glycemic control, as well as an
increased diagnosis of patients with hypertension, higher
prescription use of renoprotective treatment with ACEI,
and higher rates of blood pressure control (38). Recently,
the US Department of Health and Human Services has
introduced an ambitious program to reduce the number
of Americans developing ESRD by 25 percent by 2030.
The program, known as the Advancing American Kidney
Health Initiative, has set goals with metrics to measure its
success; among them is to increase efforts to prevent,
detect, and slow the progression of kidney disease, in part
by addressing traditional risk factors like diabetes and
hypertension. To reduce the risk of kidney failure, the
program contemplates advancing public health surveil-
lance and research to identify populations at risk and
those in early stages of kidney disease, and to encourage
adoption of evidence-based interventions to delay or stop
progression to kidney failure (39). Ongoing programs, like
the Special Diabetes Program for Indians represents an
important part of this approach by providing team-based
care and care management. Since its implementation,
the incidence of diabetes-related kidney failure among
American Native populations decreased by over 40 percent
between 2000 and 2015 (40).
Involvement of primary care physicians and
other health professionals
Detection and prevention of CKD programs require
considerable resources both in terms of manpower and
funds. Availability of such resources will depend primarily
on the leadership of nephrologists (41). However, the
number of nephrologists is not sufficient to provide renal
care to the growing number of CKD patients worldwide. It
has been suggested that most cases of non-progressive
chronic kidney disease can be managed without referral to
a nephrologist, and specialist referral can be reserved
for patients with an estimated GFR rate o30 mL min–1 
(1.73 m2)–1, rapidly declining kidney function, persistent
proteinuria, or uncontrolled hypertension or diabetes (42).
It has been demonstrated that with an educational inter-
vention the clinical competence of family physicians
increases, resulting in preserved renal function in diabetic
patients with early renal disease (43). The practitioners
who received the educational intervention used signifi-
cantly more angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, and statins than did practi-
tioners who did not receive it. The results were similar to
those found in patients treated by nephrologists (44). The
role of primary health care professionals in the implemen-
tation of CKD prevention strategies in LMIC has been
recently illustrated (45).
The e-learning has become an increasingly popular
approach to medical education. Online learning programs
for NCD prevention and treatment, including CKD, have
Braz J Med Biol Res | doi: 10.1590/1414-431X20209614
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been successfully implemented in Mexico. By 2015, over
5000 health professionals (including non-nephrologists)
had been trained using an electronic health education
platform (46).
Shortage of nephrology manpower –
implication on prevention
The resources for nephrology care remain at critical
levels in many parts of the world. Even in Western
developed countries, nephrologists are frequently in short
supply. In a selection of European countries with similar,
predominantly public, health care systems, there was a
substantial variation in the nephrology workforce. Coun-
tries like Italy, Greece, and Spain reported the highest
ratios, while countries like Ireland, Turkey, and the UK had
the lowest ones (47). In the USA, the number of nephrol-
ogists per 1000 ESRD patients has declined over the
years, from 18 in 1997 to 14 in 2010 (48). The situation in
the developing world is even worse. With the exception of
Nigeria, Sudan, Kenya, and South Africa, in many countries
of sub-Saharan Africa there are fewer than 10 nephrolo-
gists. The number of nephrology nurses and dialysis
technicians is also insufficient (49). In Latin America the
average number of nephrologists is 13.4 pmp. However,
there is unequal distribution between countries; some with
o10 nephrologists pmp (Honduras, 2.1 pmp; Guatemala,
3.3 pmp; and Nicaragua, 4.6 pmp), and some exceeding 25
pmp (Cuba, 45.2 pmp; Uruguay, 44.2 pmp; and Argentina,
26.8 pmp) (50).
The causes of this shortage are multiple. Potential
contributors to this variation include the increasing burden
of CKD, erosion of nephrology practice scope by other
specialists, lack of workforce planning in some countries
relative to others, and the development of new care delivery
models (48). A novel strategy has been the successful ISN
Fellowship program. Since its implementation in 1985, over
600 fellows from 483 LMIC have been trained. A signifi-
cant number of fellowships were undertaken in selected
developed centers within the fellow’s own region. In a recent
survey, 85% of responding fellows were re-employed by
their home institutions (51,52).
Interdisciplinary prevention approach
Since 1994, a National Institutes of Health consensus
advocated for early medical intervention in predialysis
patients. Owing to the complexity of care of CKD, it was
recommended that patients should be referred to a
multidisciplinary team consisting of nephrologist, dietitian,
nurse, social worker, and health psychologist with the aim
to reduce predialysis and dialysis morbidity and mortality
(53). In Mexico, a nurse-led, protocol driven, multidisci-
plinary program reported better preservation in eGFR and
a trend of improvement of quality of care of CKD patients
similar to those reported by other Multidisciplinary
Clinic programs in the developed world. Additionally,
more patients started dialysis non-emergently, and some
obtained a pre-emptive kidney transplant. For those
unable to obtain dialysis or who choose not to, a palliative
care program is now being implemented (54). Care
models supporting primary care providers or allied health
workers achieved better effectiveness in slowing kidney
function decline when compared to those providing spe-
cialty care. Future models should address region-specific
causes of CKD, increase the quality of diagnostic capa-
bilities, establish referral pathways, and provide better
assessments of clinical effectiveness and cost-effective-
ness (55).
Online educational programs for CKD
prevention and treatment
Whereas it is important to enhance the promotion and
implementation of ‘‘Prevention’’ of kidney disease and kidney
failure amongst healthcare professionals, it is equally im-
portant to promote ‘‘Prevention’’ with education programs for
those at risk of kidney disease and kidney failure, and for the
general population at large. It is a stepwise process, from
awareness, engagement, participation, empowerment, and
partnership. As highlighted above, in general, the health
literacy of the general population is low. Awareness and
understanding of kidney disease are inadequate. Education
is key to engaging patients with kidney disease. It is the
path to self-management and patient-centered care.
Narva et al. found patient education is associated with
better patient outcomes (56). Obstacles include the
complex nature of kidney disease information, low base-
line awareness, limited health literacy and numeracy,
limited availability of CKD information, and lack of readi-
ness to learn. New education approaches should be devel-
oped through research and quality improvement efforts.
Schatell found web-based kidney education is helpful in
supporting patient self-management (57).
The internet offers a wealth of resources on education.
Understanding the types of internet sources that CKD
patients use today can help renal professionals to point
patients in the right direction. It is important that reputable
healthcare organizations, preferably at a national level,
facilitate easier access to health information on their
websites (Supplementary Table S1). The mode of com-
munication currently used by patients and the population
at large is through the internet - websites, portals, and
other social media, such as Facebook and Twitter. There
are also free apps on popular mobile devices providing
education on kidney disease. There is no shortage of infor-
mation on the internet. The challenge is how to effec-
tively ‘‘push’’ important healthcare information in a targeted
manner, and to facilitate users seeking information in their
efforts to ‘‘pull’’ relevant and reliable information from the
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internet. It is important the ‘‘pushing’’ of health information
is targeted and specific, relevant for the condition (primary,
secondary, or tertiary prevention), and is offered at the right
time to the right recipient. It is possible with the use of
information technology and informatics to provide relevant
and targeted information for patients at high risk, coupling
the information based on diagnosis and drugs prescribed.
Engagement of professional society resources and patient
groups is a crucial step to promote community partnership
and patient empowerment on prevention. Additional
resources may be available from charitable and philan-
thropic organizations.
Renewed focus on prevention, raising
awareness, and education
Given the pressing urgency pertaining to the need for
increasing education and awareness on the importance of
the preventive measures, we suggest the following goals
to redirect the focus on plans and actions:
1. Empowerment through health literacy in order to devel-
op and support national campaigns that bring public
awareness to prevention of kidney disease.
2. Population-based approaches to manage key known
risks for kidney disease, such as blood pressure con-
trol and effective management of obesity and diabetes.
3. Implementation of the World Health Organization ‘Best
Buys’ approach including screening of at-risk popula-
tions for CKD, universal access to essential diagnos-
tics of early CKD, availability of affordable basic tech-
nologies and essential medicines, and task shifting
from doctors to front-line healthcare workers to more
effectively target progression of CKD and other
secondary preventative approaches.
To that end, the motto ‘Kidney Health for Everyone,
Everywhere’ is more than a tagline or wishful thinking. It is
an imperative policy that can be successfully achieved if
policy makers, nephrologists, and healthcare professionals
place prevention and primary care for kidney disease within
the context of their Universal Health Coverage programs.
Supplementary Material
Click here to view [pdf].
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